OpGen, Inc. has entered into a global supply agreement to use Thermo Fisher Scientific’s technology to support the commercialization of its rapid molecular products and informatics system to help combat multidrug-resistant infections. OpGen will combine Thermo’s real-time PCR solutions with its genomic analysis and bioinformatics technology to help healthcare providers rapidly and accurately identify bacterial antibiotic susceptibility using resistance gene profiles.
OpGen will commercialize the Acuitas Rapid Test for Pathogen ID and resistance genes on Thermo’s new mid-throughput real-time PCR system. The effort will be supported by local labs that will be able to interpret results using customized analysis software and OpGen’s cloud-based Acuitas Lighthouse Knowledgebase to match genomic analysis data with antibiotic susceptibility information to identify microbial infections in individual patients.
“This effort supports our commitment to advancing the latest in molecular testing to help hospitals and health systems rapidly and accurately streamline protocols for informed decision-making in acute care settings,” said Evan Jones, chairman and chief executive officer of OpGen. “Thermo Fisher’s market leading position in PCR, its global install base makes them an ideal partner for our Acuitas Rapid Test.”